|
Latest Paper:
Amruta P Barhanpurkar,
Navita Gupta,
Rupesh K Srivastava,
Geetanjali B Tomar,
Sameer P Naik,
Snehal R Joshi,
Satish T Pote,
Gyan C Mishra,
Mohan R Wani
National Center for Cell Science, University of Pune Campus, Pune 411 007, India.
IL-3 is an important cytokine that regulates hematopoiesis. We have previously demonstrated that IL-3 is a potent inhibitor of osteoclastogenesis and bone resorption. In the present study, we have investigated the role of IL-3 on human osteoblast differentiation and bone formation. We found that IL-3 in a dose-dependent manner increases osteoblast differentiation and matrix mineralization in human mesenchymal stem cells (MSCs). IL-3 significantly enhances the expression of osteoblast specific genes such as alkaline phosphatase, collagen type-I, osteocalcin and osteopontin; and Runx-2 and osterix transcription factors. Moreover, IL-3 induces the expression of bone morphogenetic protein-2 (BMP-2), and activates smad1/5/8. IL-3 enhances osteoblast differentiation and BMP-2 secretion through JAK/STAT pathway. Interestingly, IL-3 promotes in vivo bone regeneration ability of MSCs. Thus, we reveal for the first time that IL-3 enhances human osteoblast differentiation and bone formation in both in vitro and in vivo conditions, and suggest its therapeutic potential for bone formation in important bone diseases.
Rupesh K Srivastava,
Geetanjali B Tomar,
Amruta P Barhanpurkar,
Navita Gupta,
Satish T Pote,
Gyan C Mishra,
Mohan R Wani
National Centre for Cell Science, University of Pune Campus, Pune 411 007, India.
IL-3, a cytokine secreted by Th cells, functions as a link between the immune and the hematopoietic system. We previously demonstrated the potent inhibitory role of IL-3 on osteoclastogenesis, pathological bone resorption, and inflammatory arthritis. In this study, we investigated the novel role of IL-3 in development of regulatory T (Treg) cells. We found that IL-3 in a dose-dependent manner increases the percentage of Foxp3(+) Treg cells indirectly through secretion of IL-2 by non-Treg cells. These IL-3-expanded Treg cells are competent in suppressing effector T cell proliferation. Interestingly, IL-3 treatment significantly reduces the severity of arthritis and restores the loss of Foxp3(+) Treg cells in thymus, lymph nodes, and spleen in collagen-induced arthritis mice. Most significantly, we show that IL-3 decreases the production of proinflammatory cytokines IL-6, IL-17A, TNF-α, and IL-1 and increases the production of anti-inflammatory cytokines IFN-γ and IL-10 in collagen-induced arthritis mice. Thus, to our knowledge, we provide the first evidence that IL-3 play an important role in modulation of Treg cell development in both in vitro and in vivo conditions, and we suggest its therapeutic potential in the treatment of rheumatoid arthritis and other autoimmune diseases.
Navita Gupta,
Amruta P Barhanpurkar,
Geetanjali B Tomar,
Rupesh K Srivastava,
Supinder Kour,
Satish T Pote,
Gyan C Mishra,
Mohan R Wani
National Center for Cell Science, University of Pune Campus, Pune, India.
IL-3 is an important cytokine that regulates hematopoiesis and functions as a link between the immune and the hematopoietic system. In this study, we investigated the role and mechanism of IL-3 action on human osteoclast formation and bone resorption using PBMCs. PBMCs differentiate into functional osteoclasts in the presence of M-CSF and receptor activator of NF-kappaB ligand as evaluated by 23c6 expression and bone resorption. We found that IL-3 dose-dependently inhibited formation of 23c6-positive osteoclasts, bone resorption and C-terminal telopeptide of type I collagen, a collagen degradation product. The inhibitory effect of IL-3 on bone resorption was irreversible. To investigate the mechanism of IL-3 action, we analyzed the effect of IL-3 on the receptor activator of NF-kappaB and c-Fms receptors and c-Fos, PU.1, NFAT cytoplasmic 1, and RelB transcription factors essential for osteoclastogenesis. IL-3 significantly inhibited c-Fms and downregulated both PU.1 and c-Fos at both mRNA and protein level. Furthermore, IL-3-treated cells showed increased expression of dendritic cell markers CD1a and CD80 and decreased expression of monocyte/macrophage marker CD14. Interestingly, IL-3 inhibited formation of human osteoclasts derived from blood monocytes and bone marrow cells of osteoporotic individuals. Thus, IL-3 may have therapeutic potential as an antiosteolytic agent in treatment of osteoporosis.
A Adare,
S Afanasiev,
C Aidala,
N N Ajitanand,
Y Akiba,
H Al-Bataineh,
J Alexander,
A Al-Jamel,
K Aoki,
L Aphecetche,
R Armendariz,
S H Aronson,
J Asai,
E T Atomssa,
R Averbeck,
T C Awes,
B Azmoun,
V Babintsev,
G Baksay,
L Baksay,
A Baldisseri,
K N Barish,
P D Barnes,
B Bassalleck,
S Bathe,
S Batsouli,
V Baublis,
F Bauer,
A Bazilevsky,
S Belikov,
R Bennett,
Y Berdnikov,
A A Bickley,
M T Bjorndal,
J G Boissevain,
H Borel,
K Boyle,
M L Brooks,
D S Brown,
D Bucher,
H Buesching,
V Bumazhnov,
G Bunce,
J M Burward-Hoy,
S Butsyk,
S Campbell,
J-S Chai,
B S Chang,
J-L Charvet,
S Chernichenko,
J Chiba,
C Y Chi,
M Chiu,
I J Choi,
T Chujo,
P Chung,
A Churyn,
V Cianciolo,
C R Cleven,
Y Cobigo,
B A Cole,
M P Comets,
P Constantin,
M Csanád,
T Csörgo,
T Dahms,
K Das,
G David,
M B Deaton,
K Dehmelt,
H Delagrange,
A Denisov,
D d'Enterria,
A Deshpande,
E J Desmond,
O Dietzsch,
A Dion,
M Donadelli,
J L Drachenberg,
O Drapier,
A Drees,
A K Dubey,
A Durum,
V Dzhordzhadze,
Y V Efremenko,
J Egdemir,
F Ellinghaus,
W S Emam,
A Enokizono,
H En'yo,
B Espagnon,
S Esumi,
K O Eyser,
D E Fields,
M Finger,
M Finger Jr,
F Fleuret,
S L Fokin,
B Forestier,
Z Fraenkel,
J E Frantz,
A Franz,
A D Frawley,
K Fujiwara,
Y Fukao,
S-Y Fung,
T Fusayasu,
S Gadrat,
I Garishvili,
F Gastineau,
M Germain,
A Glenn,
H Gong,
M Gonin,
J Gosset,
Y Goto,
R Granier de Cassagnac,
N Grau,
S V Greene,
M Grosse Perdekamp,
T Gunji,
H-A Gustafsson,
T Hachiya,
A Hadj Henni,
C Haegemann,
J S Haggerty,
M N Hagiwara,
H Hamagaki,
R Han,
H Harada,
E P Hartouni,
K Haruna,
M Harvey,
E Haslum,
K Hasuko,
R Hayano,
M Heffner,
T K Hemmick,
T Hester,
J M Heuser,
X He,
H Hiejima,
J C Hill,
R Hobbs,
M Hohlmann,
M Holmes,
W Holzmann,
K Homma,
B Hong,
T Horaguchi,
D Hornback,
M G Hur,
T Ichihara,
K Imai,
M Inaba,
Y Inoue,
D Isenhower,
L Isenhower,
M Ishihara,
T Isobe,
M Issah,
A Isupov,
B V Jacak,
J Jia,
J Jin,
O Jinnouchi,
B M Johnson,
K S Joo,
D Jouan,
F Kajihara,
S Kametani,
N Kamihara,
J Kamin,
M Kaneta,
J H Kang,
H Kanou,
T Kawagishi,
D Kawall,
A V Kazantsev,
S Kelly,
A Khanzadeev,
J Kikuchi,
D H Kim,
D J Kim,
E Kim,
Y-S Kim,
E Kinney,
A Kiss,
E Kistenev,
A Kiyomichi,
J Klay,
C Klein-Boesing,
L Kochenda,
V Kochetkov,
B Komkov,
M Konno,
D Kotchetkov,
A Kozlov,
A Král,
A Kravitz,
P J Kroon,
J Kubart,
G J Kunde,
N Kurihara,
K Kurita,
M J Kweon,
Y Kwon,
G S Kyle,
R Lacey,
Y-S Lai,
J G Lajoie,
A Lebedev,
Y Le Bornec,
S Leckey,
D M Lee,
M K Lee,
T Lee,
M J Leitch,
M A L Leite,
B Lenzi,
H Lim,
T Liska,
A Litvinenko,
M X Liu,
X Li,
X H Li,
B Love,
D Lynch,
C F Maguire,
Y I Makdisi,
A Malakhov,
M D Malik,
V I Manko,
Y Mao,
L Masek,
H Masui,
F Matathias,
M C McCain,
M McCumber,
P L McGaughey,
Y Miake,
P Mikes,
K Miki,
T E Miller,
A Milov,
S Mioduszewski,
G C Mishra,
M Mishra,
J T Mitchell,
M Mitrovski,
A Morreale,
D P Morrison,
J M Moss,
T V Moukhanova,
D Mukhopadhyay,
J Murata,
S Nagamiya,
Y Nagata,
J L Nagle,
M Naglis,
I Nakagawa,
Y Nakamiya,
T Nakamura,
K Nakano,
J Newby,
M Nguyen,
B E Norman,
A S Nyanin,
J Nystrand,
E O'Brien,
S X Oda,
C A Ogilvie,
H Ohnishi,
I D Ojha,
H Okada,
K Okada,
M Oka,
O O Omiwade,
A Oskarsson,
I Otterlund,
M Ouchida,
K Ozawa,
R Pak,
D Pal,
A P T Palounek,
V Pantuev,
V Papavassiliou,
J Park,
W J Park,
S F Pate,
H Pei,
J-C Peng,
H Pereira,
V Peresedov,
D Yu Peressounko,
C Pinkenburg,
R P Pisani,
M L Purschke,
A K Purwar,
H Qu,
J Rak,
A Rakotozafindrabe,
I Ravinovich,
K F Read,
S Rembeczki,
M Reuter,
K Reygers,
V Riabov,
Y Riabov,
G Roche,
A Romana,
M Rosati,
S S E Rosendahl,
P Rosnet,
P Rukoyatkin,
V L Rykov,
S S Ryu,
B Sahlmueller,
N Saito,
T Sakaguchi,
S Sakai,
H Sakata,
V Samsonov,
H D Sato,
S Sato,
S Sawada,
J Seele,
R Seidl,
V Semenov,
R Seto,
D Sharma,
T K Shea,
I Shein,
A Shevel,
T-A Shibata,
K Shigaki,
M Shimomura,
T Shohjoh,
K Shoji,
A Sickles,
C L Silva,
D Silvermyr,
C Silvestre,
K S Sim,
C P Singh,
V Singh,
S Skutnik,
M Slunecka,
W C Smith,
A Soldatov,
R A Soltz,
W E Sondheim,
S P Sorensen,
I V Sourikova,
F Staley,
P W Stankus,
E Stenlund,
M Stepanov,
A Ster,
S P Stoll,
T Sugitate,
C Suire,
J P Sullivan,
J Sziklai,
T Tabaru,
S Takagi,
E M Takagui,
A Taketani,
K H Tanaka,
Y Tanaka,
K Tanida,
M J Tannenbaum,
A Taranenko,
P Tarján,
T L Thomas,
M Togawa,
A Toia,
J Tojo,
L Tomásek,
H Torii,
R S Towell,
V-N Tram,
I Tserruya,
Y Tsuchimoto,
S K Tuli,
H Tydesjö,
N Tyurin,
C Vale,
H Valle,
H W van Hecke,
J Velkovska,
R Vertesi,
A A Vinogradov,
M Virius,
V Vrba,
E Vznuzdaev,
M Wagner,
D Walker,
X R Wang,
Y Watanabe,
J Wessels,
S N White,
N Willis,
D Winter,
C L Woody,
M Wysocki,
W Xie,
Y L Yamaguchi,
A Yanovich,
Z Yasin,
J Ying,
S Yokkaichi,
G R Young,
I Younus,
I E Yushmanov,
W A Zajc,
O Zaudtke,
C Zhang,
S Zhou,
J Zimányi,
L Zolin
University of Colorado, Boulder, Colorado 80309, USA.
The production of e;{+}e;{-} pairs for m_{e;{+}e;{-}}<0.3 GeV/c;{2} and 1<p_{T}<5 GeV/c is measured in p+p and Au+Au collisions at sqrt[s_{NN}]=200 GeV. An enhanced yield above hadronic sources is observed. Treating the excess as photon internal conversions, the invariant yield of direct photons is deduced. In central Au+Au collisions, the excess of the direct photon yield over p+p is exponential in transverse momentum, with an inverse slope T=221+/-19;{stat}+/-19;{syst} MeV. Hydrodynamical models with initial temperatures ranging from T_{init} approximately 300-600 MeV at times of approximately 0.6-0.15 fm/c after the collision are in qualitative agreement with the data. Lattice QCD predicts a phase transition to quark gluon plasma at approximately 170 MeV.
Geetanjali B Tomar,
Rupesh K Srivastava,
Navita Gupta,
Amruta P Barhanpurkar,
Satish T Pote,
Hiral M Jhaveri,
Gyan C Mishra,
Mohan R Wani
National Center for Cell Science, University of Pune Campus, Pune 411 007, India.
Mesenchymal stem cells (MSCs) are capable of self-renewal and differentiation into multiple cell lineages. Presently, bone marrow is considered as a prime source of MSCs; however, there are some drawbacks and limitations in use of these MSCs for cell therapy. In this study, we demonstrate that human gingival tissue-derived MSCs have several advantages over bone marrow derived MSCs. Gingival MSCs are easy to isolate, homogenous and proliferate faster than bone marrow MSCs without any growth factor. Importantly, gingival MSCs display stable morphology and do not loose MSC characteristic at higher passages. In addition, gingival MSCs maintain normal karyotype and telomerase activity in long term cultures, and are not tumorigenic. Thus, we reveal that human gingiva is a better source of MSCs than bone marrow, and large number of functionally competent clinical grade MSCs can be generated in short duration for cell therapy in regenerative medicine and tissue engineering.
PLoS One. 2009 ;4 (12):e8245
20011600
Cit:2
Devendra Bansal,
Fabien Herbert,
Pharath Lim,
Prakash Deshpande,
Christophe Bécavin,
Vincent Guiyedi,
Ilaria de Maria,
Jean Claude Rousselle,
Abdelkader Namane,
Rajendra Jain,
Pierre-André Cazenave,
Gyan Chandra Mishra,
Cristiano Ferlini,
Constantin Fesel,
Arndt Benecke,
Sylviane Pied
Equipe PIME CNRS, Inserm U547, Institut Pasteur de Lille, Pôle Universitaire Nord, France.
BACKGROUND: The main processes in the pathogenesis of cerebral malaria caused by Plasmodium falciparum involved sequestration of parasitized red blood cells and immunopathological responses. Among immune factors, IgG autoantibodies to brain antigens are increased in P. falciparum infected patients and correlate with disease severity in African children. Nevertheless, their role in the pathophysiology of cerebral malaria (CM) is not fully defined. We extended our analysis to an Indian population with genetic backgrounds and endemic and environmental status different from Africa to determine if these autoantibodies could be either a biomarker or a risk factor of developing CM. METHODS/PRINCIPAL FINDINGS: We investigated the significance of these self-reactive antibodies in clinically well-defined groups of P. falciparum infected patients manifesting mild malaria (MM), severe non-cerebral malaria (SM), or cerebral malaria (CM) and in control subjects from Gondia, a malaria epidemic site in central India using quantitative immunoprinting and multivariate statistical analyses. A two-fold complete-linkage hierarchical clustering allows classifying the different patient groups and to distinguish the CM from the others on the basis of their profile of IgG reactivity to brain proteins defined by PANAMA Blot. We identified beta tubulin III (TBB3) as a novel discriminant brain antigen in the prevalence of CM. In addition, circulating IgG from CM patients highly react with recombinant TBB3. Overall, correspondence analyses based on singular value decomposition show a strong correlation between IgG anti-TBB3 and elevated concentration of cluster-II cytokine (IFNgamma, IL1beta, TNFalpha, TGFbeta) previously demonstrated to be a predictor of CM in the same population. CONCLUSIONS/SIGNIFICANCE: Collectively, these findings validate the relationship between antibody response to brain induced by P. falciparum infection and plasma cytokine patterns with clinical outcome of malaria. They also provide significant insight into the immune mechanisms associated to CM by the identification of TBB3 as a new disease-specific marker and potential therapeutic target.
S Afanasiev,
C Aidala,
N N Ajitanand,
Y Akiba,
J Alexander,
A Al-Jamel,
K Aoki,
L Aphecetche,
R Armendariz,
S H Aronson,
R Averbeck,
T C Awes,
B Azmoun,
V Babintsev,
A Baldisseri,
K N Barish,
P D Barnes,
B Bassalleck,
S Bathe,
S Batsouli,
V Baublis,
F Bauer,
A Bazilevsky,
S Belikov,
R Bennett,
Y Berdnikov,
M T Bjorndal,
J G Boissevain,
H Borel,
K Boyle,
M L Brooks,
D S Brown,
D Bucher,
H Buesching,
V Bumazhnov,
G Bunce,
J M Burward-Hoy,
S Butsyk,
S Campbell,
J-S Chai,
S Chernichenko,
J Chiba,
C Y Chi,
M Chiu,
I J Choi,
T Chujo,
V Cianciolo,
C R Cleven,
Y Cobigo,
B A Cole,
M P Comets,
P Constantin,
M Csanád,
T Csörgo,
T Dahms,
K Das,
G David,
H Delagrange,
A Denisov,
D d'Enterria,
A Deshpande,
E J Desmond,
O Dietzsch,
A Dion,
J L Drachenberg,
O Drapier,
A Drees,
A K Dubey,
A Durum,
V Dzhordzhadze,
Y V Efremenko,
J Egdemir,
A Enokizono,
H En'yo,
B Espagnon,
S Esumi,
D E Fields,
F Fleuret,
S L Fokin,
B Forestier,
Z Fraenkel,
J E Frantz,
A Franz,
A D Frawley,
Y Fukao,
S-Y Fung,
S Gadrat,
F Gastineau,
M Germain,
A Glenn,
M Gonin,
J Gosset,
Y Goto,
R Granier de Cassagnac,
N Grau,
S V Greene,
M Grosse Perdekamp,
T Gunji,
H-A Gustafsson,
T Hachiya,
A Hadj Henni,
J S Haggerty,
M N Hagiwara,
H Hamagaki,
H Harada,
E P Hartouni,
K Haruna,
M Harvey,
E Haslum,
K Hasuko,
R Hayano,
M Heffner,
T K Hemmick,
J M Heuser,
X He,
H Hiejima,
J C Hill,
R Hobbs,
M Holmes,
W Holzmann,
K Homma,
B Hong,
T Horaguchi,
M G Hur,
T Ichihara,
K Imai,
M Inaba,
D Isenhower,
L Isenhower,
M Ishihara,
T Isobe,
M Issah,
A Isupov,
B V Jacak,
J Jia,
J Jin,
O Jinnouchi,
B M Johnson,
K S Joo,
D Jouan,
F Kajihara,
S Kametani,
N Kamihara,
M Kaneta,
J H Kang,
T Kawagishi,
A V Kazantsev,
S Kelly,
A Khanzadeev,
D J Kim,
E Kim,
Y-S Kim,
E Kinney,
A Kiss,
E Kistenev,
A Kiyomichi,
C Klein-Boesing,
L Kochenda,
V Kochetkov,
B Komkov,
M Konno,
D Kotchetkov,
A Kozlov,
P J Kroon,
G J Kunde,
N Kurihara,
K Kurita,
M J Kweon,
Y Kwon,
G S Kyle,
R Lacey,
J G Lajoie,
A Lebedev,
Y Le Bornec,
S Leckey,
D M Lee,
M K Lee,
M J Leitch,
M A L Leite,
H Lim,
A Litvinenko,
M X Liu,
X H Li,
C F Maguire,
Y I Makdisi,
A Malakhov,
M D Malik,
V I Manko,
H Masui,
F Matathias,
M C McCain,
P L McGaughey,
Y Miake,
T E Miller,
A Milov,
S Mioduszewski,
G C Mishra,
J T Mitchell,
D P Morrison,
J M Moss,
T V Moukhanova,
D Mukhopadhyay,
J Murata,
S Nagamiya,
Y Nagata,
J L Nagle,
M Naglis,
T Nakamura,
J Newby,
M Nguyen,
B E Norman,
R Nouicer,
A S Nyanin,
J Nystrand,
E O'Brien,
C A Ogilvie,
H Ohnishi,
I D Ojha,
H Okada,
K Okada,
O O Omiwade,
A Oskarsson,
I Otterlund,
K Ozawa,
D Pal,
A P T Palounek,
V Pantuev,
V Papavassiliou,
J Park,
W J Park,
S F Pate,
H Pei,
J-C Peng,
H Pereira,
V Peresedov,
D Yu Peressounko,
C Pinkenburg,
R P Pisani,
M L Purschke,
A K Purwar,
H Qu,
J Rak,
I Ravinovich,
K F Read,
M Reuter,
K Reygers,
V Riabov,
Y Riabov,
G Roche,
A Romana,
M Rosati,
S S E Rosendahl,
P Rosnet,
P Rukoyatkin,
V L Rykov,
S S Ryu,
B Sahlmueller,
N Saito,
T Sakaguchi,
S Sakai,
V Samsonov,
H D Sato,
S Sato,
S Sawada,
V Semenov,
R Seto,
D Sharma,
T K Shea,
I Shein,
T-A Shibata,
K Shigaki,
M Shimomura,
T Shohjoh,
K Shoji,
A Sickles,
C L Silva,
D Silvermyr,
K S Sim,
C P Singh,
V Singh,
S Skutnik,
W C Smith,
A Soldatov,
R A Soltz,
W E Sondheim,
S P Sorensen,
I V Sourikova,
F Staley,
P W Stankus,
E Stenlund,
M Stepanov,
A Ster,
S P Stoll,
T Sugitate,
C Suire,
J P Sullivan,
J Sziklai,
T Tabaru,
S Takagi,
E M Takagui,
A Taketani,
K H Tanaka,
Y Tanaka,
K Tanida,
M J Tannenbaum,
A Taranenko,
P Tarján,
T L Thomas,
M Togawa,
J Tojo,
H Torii,
R S Towell,
V-N Tram,
I Tserruya,
Y Tsuchimoto,
S K Tuli,
H Tydesjö,
N Tyurin,
C Vale,
H Valle,
H W van Hecke,
J Velkovska,
R Vértesi,
A A Vinogradov,
E Vznuzdaev,
M Wagner,
X R Wang,
Y Watanabe,
J Wessels,
S N White,
N Willis,
D Winter,
C L Woody,
M Wysocki,
W Xie,
A Yanovich,
S Yokkaichi,
G R Young,
I Younus,
I E Yushmanov,
W A Zajc,
O Zaudtke,
C Zhang,
J Zimányi,
L Zolin
Joint Institute for Nuclear Research, 141980 Dubna, Moscow Region, Russia.
Bose-Einstein correlations of charged kaons are used to probe Au+Au collisions at sqrt[s_{NN}]=200 GeV and are compared to charged pion probes, which have a larger hadronic scattering cross section. Three-dimensional Gaussian source radii are extracted, along with a one-dimensional kaon emission source function. The centrality dependences of the three Gaussian radii are well described by a single linear function of N_{part};{1/3} with a zero intercept. Imaging analysis shows a deviation from a Gaussian tail at r greater, similar10 fm, although the bulk emission at lower radius is well described by a Gaussian. The presence of a non-Gaussian tail in the kaon source reaffirms that the particle emission region in a heavy-ion collision is extended, and that similar measurements with pions are not solely due to the decay of long-lived resonances.
National Centre for Cell Science, NCCS Complex, Pune, India.
Fenugreek (Trigonella foenum-graecum) seeds, used as a condiment, are documented for health benefits including amelioration of abnormalities in lipid homeostasis due to its hypolipidemic properties. However, molecular mechanisms underlying the hypolipidemic effect of fenugreek seeds remain obscure. In this study, hypolipidemic effect of a novel thermostable extract of fenugreek seeds (TEFS) was evaluated in vitro by employing differentiating and differentiated 3T3-L1 cells, and HepG2 cells cultured in normal or sterol-enriched conditions. Hypolipidemic effect was studied by quantifying decrease in accumulation of fat or by western blot analysis of adipogenic and lipogenic factors. At molecular level, TEFS inhibited accumulation of fat in differentiating and differentiated 3T3-L1 cells via decreased expression of adipogenic factors such as peroxisome proliferators activated-receptor-gamma (PPAR-gamma), sterol regulatory element-binding protein-1 (SREBP-1), and CAAT element-binding proteins-alpha (c/EBP-alpha). We also show that following TEFS treatment, cellular triglycerides (TGs), and cholesterol concentrations decreased significantly (P < 0.05) in HepG2 cells via reduced expression of SREBP-1, at mRNA as well as protein level. Under sterol enriched condition, TEFS upregulated low-density lipoprotein receptor (LDLR) expression resulting in enhanced LDL uptake. Treating fat supplement fed C57BL6/J mice with TEFS for 15 days resulted in decrease of serum TG, LDL-cholesterol (LDLc), and body weight in a dose- and time-dependent manner (P < 0.05). Results indicate that hypolipidemic effect of TEFS is due to inhibition of fat accumulation and upregulation of LDLR. Taken together, the study suggests that TEFS may have potential application in the management of dyslipidemia and its associated metabolic disorders.
A Adare,
S Afanasiev,
C Aidala,
N N Ajitanand,
Y Akiba,
H Al-Bataineh,
J Alexander,
A Al-Jamel,
K Aoki,
L Aphecetche,
R Armendariz,
S H Aronson,
J Asai,
E T Atomssa,
R Averbeck,
T C Awes,
B Azmoun,
V Babintsev,
G Baksay,
L Baksay,
A Baldisseri,
K N Barish,
P D Barnes,
B Bassalleck,
S Bathe,
S Batsouli,
V Baublis,
F Bauer,
A Bazilevsky,
S Belikov,
R Bennett,
Y Berdnikov,
A A Bickley,
M T Bjorndal,
J G Boissevain,
H Borel,
K Boyle,
M L Brooks,
D S Brown,
D Bucher,
H Buesching,
V Bumazhnov,
G Bunce,
J M Burward-Hoy,
S Butsyk,
S Campbell,
J-S Chai,
B S Chang,
J-L Charvet,
S Chernichenko,
J Chiba,
C Y Chi,
M Chiu,
I J Choi,
T Chujo,
P Chung,
A Churyn,
V Cianciolo,
C R Cleven,
Y Cobigo,
B A Cole,
M P Comets,
P Constantin,
M Csanád,
T Csörgo,
T Dahms,
K Das,
G David,
M B Deaton,
K Dehmelt,
H Delagrange,
A Denisov,
D d'Enterria,
A Deshpande,
E J Desmond,
O Dietzsch,
A Dion,
M Donadelli,
J L Drachenberg,
O Drapier,
A Drees,
A K Dubey,
A Durum,
V Dzhordzhadze,
Y V Efremenko,
J Egdemir,
F Ellinghaus,
W S Emam,
A Enokizono,
H En'yo,
B Espagnon,
S Esumi,
K O Eyser,
D E Fields,
M Finger,
M Finger Jr,
F Fleuret,
S L Fokin,
B Forestier,
Z Fraenkel,
J E Frantz,
A Franz,
A D Frawley,
K Fujiwara,
Y Fukao,
S-Y Fung,
T Fusayasu,
S Gadrat,
I Garishvili,
F Gastineau,
M Germain,
A Glenn,
H Gong,
M Gonin,
J Gosset,
Y Goto,
R Granier de Cassagnac,
N Grau,
S V Greene,
M Grosse Perdekamp,
T Gunji,
H-A Gustafsson,
T Hachiya,
A Hadj Henni,
C Haegemann,
J S Haggerty,
M N Hagiwara,
H Hamagaki,
R Han,
H Harada,
E P Hartouni,
K Haruna,
M Harvey,
E Haslum,
K Hasuko,
R Hayano,
M Heffner,
T K Hemmick,
T Hester,
J M Heuser,
X He,
H Hiejima,
J C Hill,
R Hobbs,
M Hohlmann,
M Holmes,
W Holzmann,
K Homma,
B Hong,
T Horaguchi,
D Hornback,
M G Hur,
T Ichihara,
K Imai,
J Imrek,
M Inaba,
Y Inoue,
D Isenhower,
L Isenhower,
M Ishihara,
T Isobe,
M Issah,
A Isupov,
B V Jacak,
J Jia,
J Jin,
O Jinnouchi,
B M Johnson,
K S Joo,
D Jouan,
F Kajihara,
S Kametani,
N Kamihara,
J Kamin,
M Kaneta,
J H Kang,
H Kanou,
T Kawagishi,
D Kawall,
A V Kazantsev,
S Kelly,
A Khanzadeev,
J Kikuchi,
D H Kim,
D J Kim,
E Kim,
Y-S Kim,
E Kinney,
A Kiss,
E Kistenev,
A Kiyomichi,
J Klay,
C Klein-Boesing,
L Kochenda,
V Kochetkov,
B Komkov,
M Konno,
D Kotchetkov,
A Kozlov,
A Král,
A Kravitz,
P J Kroon,
J Kubart,
G J Kunde,
N Kurihara,
K Kurita,
M J Kweon,
Y Kwon,
G S Kyle,
R Lacey,
Y-S Lai,
J G Lajoie,
A Lebedev,
Y Le Bornec,
S Leckey,
D M Lee,
M K Lee,
T Lee,
M J Leitch,
M A L Leite,
B Lenzi,
H Lim,
T Liska,
A Litvinenko,
M X Liu,
X Li,
X H Li,
B Love,
D Lynch,
C F Maguire,
Y I Makdisi,
A Malakhov,
M D Malik,
V I Manko,
Y Mao,
L Masek,
H Masui,
F Matathias,
M C McCain,
M McCumber,
P L McGaughey,
Y Miake,
P Mikes,
K Miki,
T E Miller,
A Milov,
S Mioduszewski,
G C Mishra,
M Mishra,
J T Mitchell,
M Mitrovski,
A Morreale,
D P Morrison,
J M Moss,
T V Moukhanova,
D Mukhopadhyay,
J Murata,
S Nagamiya,
Y Nagata,
J L Nagle,
M Naglis,
I Nakagawa,
Y Nakamiya,
T Nakamura,
K Nakano,
J Newby,
M Nguyen,
B E Norman,
A S Nyanin,
J Nystrand,
E O'Brien,
S X Oda,
C A Ogilvie,
H Ohnishi,
I D Ojha,
H Okada,
K Okada,
M Oka,
O O Omiwade,
A Oskarsson,
I Otterlund,
M Ouchida,
K Ozawa,
R Pak,
D Pal,
A P T Palounek,
V Pantuev,
V Papavassiliou,
J Park,
W J Park,
S F Pate,
H Pei,
J-C Peng,
H Pereira,
V Peresedov,
D Yu Peressounko,
C Pinkenburg,
R P Pisani,
M L Purschke,
A K Purwar,
H Qu,
J Rak,
A Rakotozafindrabe,
I Ravinovich,
K F Read,
S Rembeczki,
M Reuter,
K Reygers,
V Riabov,
Y Riabov,
G Roche,
A Romana,
M Rosati,
S S E Rosendahl,
P Rosnet,
P Rukoyatkin,
V L Rykov,
S S Ryu,
B Sahlmueller,
N Saito,
T Sakaguchi,
S Sakai,
H Sakata,
V Samsonov,
H D Sato,
S Sato,
S Sawada,
J Seele,
R Seidl,
V Semenov,
R Seto,
D Sharma,
T K Shea,
I Shein,
A Shevel,
T-A Shibata,
K Shigaki,
M Shimomura,
T Shohjoh,
K Shoji,
A Sickles,
C L Silva,
D Silvermyr,
C Silvestre,
K S Sim,
C P Singh,
V Singh,
S Skutnik,
M Slunecka,
W C Smith,
A Soldatov,
R A Soltz,
W E Sondheim,
S P Sorensen,
I V Sourikova,
F Staley,
P W Stankus,
E Stenlund,
M Stepanov,
A Ster,
S P Stoll,
T Sugitate,
C Suire,
J P Sullivan,
J Sziklai,
T Tabaru,
S Takagi,
E M Takagui,
A Taketani,
K H Tanaka,
Y Tanaka,
K Tanida,
M J Tannenbaum,
A Taranenko,
P Tarján,
T L Thomas,
M Togawa,
A Toia,
J Tojo,
L Tomásek,
H Torii,
R S Towell,
V-N Tram,
I Tserruya,
Y Tsuchimoto,
S K Tuli,
H Tydesjö,
N Tyurin,
C Vale,
H Valle,
H W van Hecke,
J Velkovska,
R Vertesi,
A A Vinogradov,
M Virius,
V Vrba,
E Vznuzdaev,
M Wagner,
D Walker,
X R Wang,
Y Watanabe,
J Wessels,
S N White,
N Willis,
D Winter,
C L Woody,
M Wysocki,
W Xie,
Y L Yamaguchi,
A Yanovich,
Z Yasin,
J Ying,
S Yokkaichi,
G R Young,
I Younus,
I E Yushmanov,
W A Zajc,
O Zaudtke,
C Zhang,
S Zhou,
J Zimányi,
L Zolin
University of Colorado, Boulder, Colorado 80309, USA.
For Au+Au collisions at 200 GeV, we measure neutral pion production with good statistics for transverse momentum, p_{T}, up to 20 GeV/c. A fivefold suppression is found, which is essentially constant for 5<p_{T}<20 GeV/c. Experimental uncertainties are small enough to constrain any model-dependent parametrization for the transport coefficient of the medium, e.g., q[over ;] in the parton quenching model. The spectral shape is similar for all collision classes, and the suppression does not saturate in Au+Au collisions.
S D Yogesha,
Shruti M Khapli,
Rupesh K Srivastava,
Latha S Mangashetti,
Satish T Pote,
Gyan C Mishra,
Mohan R Wani
National Center for Cell Science, University of Pune Campus, Pune, India.
IL-3, a cytokine secreted by activated T cells is well known to regulate the proliferation, differentiation, and survival of pluripotent hematopoietic stem cells. IL-3 functions as a link between the immune and the hematopoietic system. In this study, we suggest an important new role of IL-3 in inhibition of TNF-alpha-induced bone resorption in vitro and prevention of inflammatory arthritis in mice. We show here that IL-3 potently and irreversibly inhibits TNF-alpha-induced bone resorption in hematopoietic precursors of monocyte/macrophage lineage. IL-3 showed an inhibitory effect on TNF-alpha-induced bone resorption even in the presence of proinflammatory cytokines such as IL-1alpha, TGF-beta(1), TGF-beta(3), IL-6, and PGE(2). We found that IL-3 prevented TNF-alpha-induced c-fos nuclear translocation and AP-1 DNA-binding activity. Interestingly, IL-3 pretreatment prevented the development of inflammatory arthritis in mice induced by a mixture of anti-type II collagen mAbs and LPS. Furthermore, IL-3 prevented cartilage and bone loss in the joints indirectly through inhibition of inflammation. Thus, we provide the first evidence that IL-3, a strong regulator of hematopoiesis, also plays an important role in inhibition of TNF-alpha-induced bone resorption and prevention of inflammatory arthritis in mice.
|
Polish News | |||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
|
|